# Pharmacokinetics and Pharmacodynamics of Emicizumab in Hemophilia A

## Emicizumab exhibits predictable, dose-proportional pharmacokinetics with sustained plasma concentrations that produce FVIII-equivalent hemostatic activity and reduce bleeding rates by 94% through an exposure-response relationship plateauing above 30 µg/mL.

## Abstract

Emicizumab demonstrates dose-proportional, predictable pharmacokinetics across diverse hemophilia A populations, with subcutaneous administration achieving sustained trough concentrations of 42-66 µg/mL during maintenance dosing across weekly (1.5 mg/kg), every-2-weeks (3 mg/kg), and every-4-weeks (6 mg/kg) regimens. The median elimination half-life is 23-30 days, with time to steady-state of 12 weeks with loading doses and 24 weeks without. Interindividual variability in trough concentrations is moderate (32%), influenced primarily by body weight, age, albumin levels, and rarely by neutralizing antibodies. Infants achieve higher concentrations (60-65 µg/mL) than older individuals with identical dosing, while bioavailability decreases after age 65. Pharmacodynamically, emicizumab maintains FVIII-equivalent activity of 17-25 IU/dL, thrombin generation >100 nM, and normalized aPTT without affecting FIX, FX, or coagulation activation markers.

Exposure-response modeling establishes that bleeding control plateaus above emicizumab concentrations of 30 µg/mL (IC50 3.58 µg/mL), explaining equivalent efficacy across dosing regimens that achieve mean concentrations of 53.5 µg/mL and produce a 94% reduction in annualized bleeding rates. Clinical studies demonstrate annualized bleeding rates for treated bleeds of 0.4-2.4, with 54-78% of patients achieving zero treated bleeds. The safety profile is favorable, with injection site reactions as the most common adverse event (16-22%), no thromboembolic events when used alone, and minimal immunogenicity. These pharmacokinetic and pharmacodynamic characteristics support body weight-based dosing without routine therapeutic drug monitoring, with potential for individualized dosing in patients maintaining concentrations substantially above the 30 µg/mL efficacy threshold.

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. More on methods

## Screening

We screened in sources based on their abstracts that met these criteria:

- **Population - Hemophilia A**: Does the study include patients diagnosed with hemophilia A?
- **Intervention - Emicizumab**: Does the study investigate emicizumab as the primary intervention?
- **Outcome - PK/PD Data**: Does the study report pharmacokinetic data (e.g., plasma concentrations, clearance, half-life, bioavailability) and/or pharmacodynamic data (e.g., factor VIII mimetic activity, bleeding rates, coagulation parameters)?
- **Study Population - Human Subjects**: Is the study conducted in human subjects (not animal or in vitro studies)?
- **Study Design**: Is the study a clinical trial (Phase I, II, III, IV), observational study, case series, case report, systematic review, or meta-analysis?
- **Intervention Specificity**: Does the study include emicizumab as an intervention (not focusing solely on other hemophilia treatments without emicizumab)?
- **Population Specificity**: Does the study include hemophilia A participants (not exclusively patients with hemophilia B or other bleeding disorders without any hemophilia A participants)?
- **Data Relevance**: Does the study report pharmacokinetic and/or pharmacodynamic data (not only clinical efficacy or safety outcomes without PK/PD data)?

## Results

### Characteristics of Included Studies

The review included 10 sources examining emicizumab pharmacokinetics and pharmacodynamics in hemophilia A, comprising clinical trial reports, a systematic review, and an exposure-response modeling study. The studies varied in design from Phase I dose-escalation trials to Phase III pivotal studies and represented diverse patient populations.

| Study | Full text retrieved? | Study Type | Population | Sample Size (PK/PD) | Study Design |
|---|---|---|---|---|---|
| C. Schmitt et al., 2020 | Yes | Primary study (Phase III) | Adults/adolescents (12-75 years) with severe HA and FVIII inhibitors; multicenter (14 countries) | 112 | Open-label, multicenter, randomized |
| A. Kiialainen et al., 2023 | No (abstract only) | Pooled analysis | HAVEN 1-4 participants | Not specified | Phase III trials |
| M. Shima et al., 2016 | No (abstract only) | Primary study (Phase I) | Japanese adults with severe HA with/without inhibitors | 18 | Open-label, non-randomized, dose-escalation |
| M. Shima et al., 2017 | Yes | Primary study (Phase I/II extension) | Japanese adults (12-58 years) with severe HA with/without inhibitors | 18 | Open-label, long-term extension |
| S. Pipe et al., 2022 | No (abstract only) | Primary study (Phase IIIb interim) | Infants ≤12 months with severe HA without inhibitors | 52 | Multi-center, open-label (HAVEN 7) |
| Qianqian Mao et al., 2025 | No (abstract only) | Primary study (retrospective) | Chinese pediatric patients (0.93-16.25 years) with HA | 46 | Retrospective single-center |
| S. Pipe et al., 2023 | No (abstract only) | Primary study (Phase IIIb primary) | Infants ≤12 months with severe HA without inhibitors | 55 | Multi-center, open-label (HAVEN 7) |
| A. Donners et al., 2021 | Yes | Systematic review | Adults and children (0 to ≥12 years) with HA with/without inhibitors | 469 PwHA, 140 volunteers | Systematic review of 15 studies |
| S. Pipe et al., 2019 | No (abstract only) | Primary study (Phase III) | Adults/adolescents (≥12 years) with severe HA with/without inhibitors from 6 countries | 41 (expansion cohort) | Multi-center, open-label, two-stage (HAVEN 4) |
| F. Jonsson et al., 2021 | Yes | Modeling study | 445 PwHA with/without inhibitors (age 1-77 years) | 385 emicizumab-treated | Exposure-response modeling of pooled Phase III data |

### Dosing Regimens and Administration

Emicizumab was administered subcutaneously across all studies, with various loading and maintenance regimens tested to optimize pharmacokinetic profiles.

| Study | Loading Dose | Maintenance Dose | Dosing Frequency | Duration |
|---|---|---|---|---|
| C. Schmitt et al., 2020 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg | Once weekly | Median 60.5 weeks (range 3.3-94.2) |
| A. Kiialainen et al., 2023 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg, 3 mg/kg, or 6 mg/kg | Weekly, Q2W, or Q4W | Not specified |
| M. Shima et al., 2016 | None mentioned | 0.3, 1.0, or 3.0 mg/kg | Weekly | 12 weeks |
| M. Shima et al., 2017 | 1 mg/kg (cohort 1), 3 mg/kg (cohort 2) | 0.3, 1.0, or 3.0 mg/kg | Once weekly | Up to 33.3 months |
| S. Pipe et al., 2022 | 3 mg/kg weekly for 4 weeks | 3 mg/kg | Every 2 weeks for 52 weeks | ≥52 weeks with 7-year follow-up |
| Qianqian Mao et al., 2025 | Median 2.85 mg/kg per week (range 2.14-3.90) | Median 5.21 mg/kg (range 2.54-6.46) | Loading: weekly; Maintenance: every 28 days | December 2023-July 2025 |
| S. Pipe et al., 2023 | 3 mg/kg weekly for 4 weeks | 3 mg/kg, 1.5 mg/kg, or 6 mg/kg | Q2W for 52 weeks; then weekly or Q4W options | ≥52 weeks with 7-year follow-up |
| A. Donners et al., 2021 | Not mentioned | 1.5 mg/kg, 3 mg/kg, or 6 mg/kg | Weekly (75%), Q2W (11%), Q4W (14%) | ≥16 weeks |
| S. Pipe et al., 2019 | 3 mg/kg weekly for 4 weeks | 6 mg/kg | Every 4 weeks | ≥24 weeks |
| F. Jonsson et al., 2021 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg, 3 mg/kg, or 6 mg/kg | Once weekly, Q2W, or Q4W | 365.25 days for ABR calculation |

## Pharmacokinetic Parameters

Emicizumab demonstrated predictable, dose-proportional pharmacokinetics across diverse patient populations.

### Plasma Concentrations

| Study | Steady-State Trough Concentrations | Peak/Loading Concentrations | Time to Steady-State |
|---|---|---|---|
| C. Schmitt et al., 2020 | ≥50 µg/mL maintained; mean 54.1 µg/mL after loading, sustained >50 µg/mL | Not specified | Not specified |
| A. Kiialainen et al., 2023 | 42.1-52.3 µg/mL with maintenance dosing | Mean 52.9 µg/mL (SD 13.6) at week 5 | Not specified |
| M. Shima et al., 2016 | Increased in dose-dependent manner | Not specified | Not specified |
| M. Shima et al., 2017 | 10.3 mg/mL (cohort 1), 29.9 mg/mL (cohort 2), 120 mg/mL (cohort 3) | Not specified | ~12 weeks with loading, 24 weeks without |
| S. Pipe et al., 2022 | 60-65 µg/mL maintained | Mean 63.2 µg/mL (95% CI: 59.5-66.8) at Week 5 | Not specified |
| Qianqian Mao et al., 2025 | Maintenance: median 50.6 µg/mL (range 17.3-81.7) | Loading: median 57.7 µg/mL (range 31.8-79.9) | Not specified |
| S. Pipe et al., 2023 | Sustained at 57-66 µg/mL | Mean 62.0 µg/mL (95% CI: 58.3-65.6) at Week 5 | Not specified |
| A. Donners et al., 2021 | Moderate interindividual variability (32%) | Not specified | Not specified |
| S. Pipe et al., 2019 | Not specified | Not specified | Not specified |
| F. Jonsson et al., 2021 | ~50 µg/mL across regimens; trough: 28.4 (QW), 24.9 (Q2W), 17.7 (Q4W) µg/mL | Not specified | Not specified |

### Pharmacokinetic Variability

Interindividual variability in trough concentrations was moderate at 32% and remained consistent across various subgroups including FVIII inhibitor status, age group, and dosing interval. Total PK interindividual variability was approximately 60%, influenced by body weight, neutralizing antidrug antibodies, age, and albumin levels.

## Pharmacodynamic Outcomes

### FVIII-Equivalent Activity and Coagulation Parameters

| Study | FVIII-Equivalent Activity (IU/dL) | aPTT Response | Thrombin Generation (nM) | Other Coagulation Parameters |
|---|---|---|---|---|
| C. Schmitt et al., 2020 | Remained above 20 U/dL | Normalized at subtherapeutic concentrations | Peak height above 100 nM | FIX, FX, fibrinogen, PT, D-dimer, PF1.2 not significantly affected |
| A. Kiialainen et al., 2023 | 25.2 IU/dL at week 5, sustained 17-23 IU/dL | Shortened following first dose | 115.2 nM at week 5, sustained >116 nM | Not mentioned |
| M. Shima et al., 2016 | Not mentioned | Remained short throughout | Not mentioned | No clinically relevant coagulation abnormalities |
| M. Shima et al., 2017 | Not mentioned | Remained short, within or shorter than reference range | Promotion of FXIa-triggered thrombin generation | Not mentioned |
| S. Pipe et al., 2022 | 21 U/dL during loading, sustained | Normalized by Week 3 | Increased to 100 nM from Week 17 onwards | FIX and FX unaffected |
| Qianqian Mao et al., 2025 | Loading: 14.6 IU/dL (range 7.4-39.2); Maintenance: 20.2 IU/dL (range 8.9-39.6) | Not mentioned | Not mentioned | Not mentioned |
| S. Pipe et al., 2023 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| A. Donners et al., 2021 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| S. Pipe et al., 2019 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |

### Bleeding Outcomes

| Study | Treated Bleeds ABR (95% CI) | All Bleeds ABR (95% CI) | Treated Joint Bleeds ABR (95% CI) | Zero Treated Bleeds (%) |
|---|---|---|---|---|
| C. Schmitt et al., 2020 | 87% reduction vs. no prophylaxis | Not specified | Not specified | 62.9% |
| M. Shima et al., 2016 | Cohort 1: 32.5→4.4; Cohort 2: 18.3→0.0; Cohort 3: 15.2→0.0 | Not specified | Not specified | 73% (with inhibitors), 71% (without) |
| M. Shima et al., 2017 | Median: Cohort 1: 1.4; Cohort 2: 0.2; Cohort 3: 0 | Not specified | Not specified | 8/18 patients (44%) |
| S. Pipe et al., 2022 | 0.4 (0.23-0.65) | 1.9 (1.35-2.68) | 0.1 (0.01-0.22) | 77.8% |
| Qianqian Mao et al., 2025 | Median ABR: 0 | Not specified | Not specified | Not specified |
| S. Pipe et al., 2023 | 0.4 (0.30-0.63) | 2.0 (1.49-2.66) | 0.0 (0.01-0.09) | 54.5% |
| A. Donners et al., 2021 | At 30 µg/mL: 2.4; At 50 µg/mL: 1.9 | Not specified | At 30 µg/mL: 1.1; At 50 µg/mL: 1.0 | 70.8%→80.2% after 1 year |
| S. Pipe et al., 2019 | 2.4 (1.4-4.3) | 4.5 (3.1-6.6) | 1.7 (0.8-3.7) | 56.1% (39.7-71.5) |
| F. Jonsson et al., 2021 | Predicted mean: 1.28 at 53.5 µg/mL (94% reduction from baseline) | Not specified | Not specified | Not specified |

### Exposure-Response Relationships

Several studies characterized the relationship between emicizumab concentrations and clinical outcomes, demonstrating clear concentration-dependent effects on both pharmacodynamic biomarkers and bleeding control.

### Concentration-Biomarker Correlations

FVIII-like activity and thrombin generation peak height correlated with emicizumab concentrations. The Chinese pediatric study quantified this relationship, finding a positive correlation between emicizumab concentration and FVIII-equivalent activity by linear regression (Y = 0.9569·X + 33.24, R² = 0.37, p < 0.01) and Spearman correlation (ρ = 0.56, p < 0.01). The relationship between emicizumab plasma concentration and aPTT was well described by an inhibitory Emax model.

## Factors Affecting Pharmacokinetics and Pharmacodynamics

### Body Weight and Size Effects

Body weight was a significant covariate affecting emicizumab pharmacokinetics across multiple studies. Dosing regimens were universally based on body weight (mg/kg), and including body weight in population PK models significantly reduced interindividual variability in both clearance (CL/F) and volume of distribution (V/F).

### Age Effects

Age emerged as an important covariate affecting emicizumab pharmacokinetics and potentially pharmacodynamics. Bioavailability decreased with age, particularly after 65 years.

### Safety and Immunogenicity

Emicizumab demonstrated a favorable safety profile across all studies, with most adverse events being mild and not leading to treatment discontinuation.

### Summary

The pharmacokinetic and pharmacodynamic characteristics of emicizumab demonstrate remarkable consistency across diverse populations and study designs, supporting its use as a prophylactic treatment for hemophilia A.